Pre-market Hot Trades in US Stocks
Virax Biolabs is up 31.91% in pre-market trading. Based on recent news,
<ol>
<li>
On May 19, Virax Biolabs had a market capitalization of $4.79 million, and its stock has dropped 78.04% over the past 12 months. Currently, the relative strength index (RSI) for VRAX is 69.52, indicating that the stock shows some upward potential in technical analysis. Source: Benzinga
</li>
<li>
On May 19, the trading price of Virax Biolabs' stock was close to its 52-week low, just 13% away from its high. This low price attracted some investors' attention, driving the stock price up. Source: Benzinga
</li>
<li>
On May 19, Benzinga's Edge stock ranking showed that the price trend for VRAX was negative across all time frames. However, there was significant price volatility in pre-market trading, possibly related to the market's reassessment of its future potential. Source: Benzinga The biotechnology industry has shown recent volatility, and investors should be cautious.
</li>
</ol>
PulteGroup is down 16.78% in pre-market trading, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Top Gainers in Pre-market US Stocks
Amesite is up 89.61% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 18, Amesite's CEO Ann Marie Sastry purchased 174,216 shares of common stock at a price of $1.44 per share. This move increased market confidence in the company's management, driving the stock price up. Source: EDGAR
</li>
<li>
On May 18, director George Parmer purchased 243,902 shares of common stock, also at a price of $1.44 per share. This further enhanced investor confidence in the company's future development, resulting in a stock price increase. Source: EDGAR
</li>
<li>
On May 18, the company released its financial report showing that, although the net loss narrowed to $2.05 million, there are still significant doubts about its ongoing operations. The market reacted positively to the company's strategic transformation, leading to a rise in stock price. Source: SEC 10-Q Industry transformation, with significant capital inflow.
</li>
</ol>
MetaVia is up 63.06% in pre-market trading. MetaVia is up 63.06% in pre-market trading. There is no significant news recently; trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news
Onconetix is up 35.46% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 19, Onconetix's stock price rose 23.65% in after-hours trading, following an 18.26% drop in regular trading. This fluctuation is related to operational updates from its Swiss subsidiary Proteomedix AG, which has developed the Proclarix blood test for detecting clinically significant prostate cancer
This update has enhanced market confidence in its products, driving the stock price up. Source: Benzinga
</li>
<li>
On May 19, Onconetix's Relative Strength Index (RSI) was 26.54, indicating a negative price trend and at an annual low. This technical indicator reflects market pessimism towards the stock, which may influence investor decisions. Source: Benzinga
</li>
<li>
On May 15, Onco-Innovations Ltd. released relevant content through ACCESS Newswire, emphasizing the independence and accountability of its information. This announcement may impact market sentiment. Source: Public Technologies The biotechnology industry is experiencing increased volatility, requiring attention to risks
</li>
</ol>

VRAX

Virax Biolabs pre-market up 31.91%; PulteGroup pre-market down 16.78%; Amesite pre-market up 89.61%; MetaVia pre-market up 63.06%; Onconetix pre-market up 35.46%

Price Alert

Virax Biolabs

Pre-market hot trades in US stocks: Virax Biolabs pre-market up 31.91%; PulteGroup pre-market down 16.78%